Impact of body weight on mycophenolic acid population pharmacokinetics in paediatric lupus nephritis: a pharmacogenomic integration study.

ABSTRACT:

Background

Mycophenolic acid (MPA) is recommended for the treatment of lupus nephritis (LN). However, the high pharmacokinetic (PK) variability of MPA contributes to its suboptimal efficacy and an increased incidence of adverse reactions. Rare data reported the impacts of genetic and clinical characteristics on MPA clearance in the paediatric patients with LN.

Methods

Paediatric patients with LN receiving mycophenolate mofetil (MMF) were prospectively enrolled. MPA PK parameters were calculated on reaching steady state (defined as at least 7 days), based on plasma concentrations measured before and after administration at intervals of 0.5, 1.5, 2.5, 4, 6, 9 and 12 hours post-MMF treatment. Genetic variants associated with the MPA PK process were identified. The population PK

SUBMITTER: Ye C 

PROVIDER: S-EPMC12215139 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature